Invitae (NYSE:NVTA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Invitae (NYSE:NVTAFree Report) in a research report sent to investors on Monday. The brokerage issued a hold rating on the medical research company’s stock.

Invitae Price Performance

NYSE NVTA opened at $0.00 on Monday. The company has a market capitalization of $267,010.00, a P/E ratio of 0.00 and a beta of 1.59. Invitae has a 1-year low of $0.02 and a 1-year high of $0.02.

Institutional Trading of Invitae

A number of large investors have recently made changes to their positions in the stock. Vestmark Advisory Solutions Inc. purchased a new stake in Invitae in the 4th quarter worth approximately $526,000. SG Americas Securities LLC boosted its holdings in shares of Invitae by 90.7% during the fourth quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock worth $58,000 after purchasing an additional 43,717 shares during the last quarter. Prosperity Wealth Management Inc. purchased a new stake in shares of Invitae in the fourth quarter valued at $144,000. Bourne Lent Asset Management Inc. increased its stake in Invitae by 53.3% in the fourth quarter. Bourne Lent Asset Management Inc. now owns 574,600 shares of the medical research company’s stock valued at $360,000 after purchasing an additional 199,900 shares during the last quarter. Finally, Green Alpha Advisors LLC lifted its position in Invitae by 138.4% during the fourth quarter. Green Alpha Advisors LLC now owns 452,585 shares of the medical research company’s stock worth $284,000 after buying an additional 262,760 shares during the period. Institutional investors and hedge funds own 61.28% of the company’s stock.

About Invitae

(Get Free Report)

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.

Featured Stories

Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.